Nonsense-Mediated Decay Targeted RNA (ntRNA): Proposal of a ntRNA–miRNA–lncRNA Triple Regulatory Network Usable as Biomarker of Prognostic Risk in Patients with Kidney Cancer

Zhou，Zhiyue1; Hu，Fuyan1; Huang，Dan2; Chi，Qingjia3; Tang，Nelson L.S.4,5,6

2022-09-01

10.3390/genes13091656

Genes   Impact Factor & Quartile

2073-4425

The most prevalent subtype of renal cell carcinoma (RCC), kidney renal clear cell carcinoma (KIRC) may be associated with a poor prognosis in a high number of cases, with a stage-specific prognostic stratification currently in use. No reliable biomarkers have been utilized so far in clinical practice despite the efforts in biomarker research in the last years. Nonsense-mediated mRNA decay (NMD) is a critical safeguard against erroneous transcripts, particularly mRNA transcripts containing premature termination codons (called nonsense-mediated decay targeted RNA, ntRNA). In this study, we first characterized 296 differentially expressed ntRNAs that were independent of the corresponding gene, 261 differentially expressed miRNAs, and 4653 differentially expressed lncRNAs. Then, we constructed a hub ntRNA–miRNA–lncRNA triple regulatory network associated with the prognosis of KIRC. Moreover, the results of immune infiltration analysis indicated that this network may influence the changes of the tumor immune microenvironment. A prognostic model derived from the genes and immune cells associated with the network was developed to distinguish between high- and low-risk patients, which was a better prognostic than other models, constructed using different biomarkers. Additionally, correlation of methylation and ntRNAs in the network suggested that some ntRNAs were regulated by methylation, which is helpful to further study the causes of abnormal expression of ntRNAs. In conclusion, this study highlighted the possible clinical implications of ntRNA functions in KIRC, proposing potential significant biomarkers that could be utilized to define the prognosis and design personalized treatment plans in kidney cancer management in the next future.

kidney renal clear cell carcinoma nonsense-mediated decay targeted RNA ntRNA–miRNA–lncRNA triple regulatory network prognostic model

SCI

English

Others

Fundamental Research Funds for the Central Universities[2020IA005];Fundamental Research Funds for the Central Universities[2020IB003];Fundamental Research Funds for the Central Universities[2020IVB031];Fundamental Research Funds for the Central Universities[2021III062JC];National Natural Science Foundation of China[61903285];

Genetics & Heredity

Genetics & Heredity

WOS:000858296300001

MDPI

2-s2.0-85138425574

Scopus

1.Department of Statistics,School of Science,Wuhan University of Technology,Wuhan,122 Luoshi Road,430070,China
2.Department of Biology,Southern University of Science and Technology,Shenzhen,518055,China
3.Department of Engineering Structure and Mechanics,School of Science,Wuhan University of Technology,Wuhan,430070,China
4.Department of Chemical Pathology and Li Ka Shing Institute of Health Sciences,Faculty of Medicine,The Chinese University of Hong Kong,Hong Kong
5.Functional Genomics and Biostatistical Computing Laboratory,CUHK Shenzhen Research Institute,Shenzhen,518000,China
6.Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics,School of Biomedical Sciences,The Chinese University of Hong Kong,Hong Kong

Zhou，Zhiyue,Hu，Fuyan,Huang，Dan,等. Nonsense-Mediated Decay Targeted RNA (ntRNA): Proposal of a ntRNA–miRNA–lncRNA Triple Regulatory Network Usable as Biomarker of Prognostic Risk in Patients with Kidney Cancer[J]. Genes,2022,13(9).

Zhou，Zhiyue,Hu，Fuyan,Huang，Dan,Chi，Qingjia,&Tang，Nelson L.S..(2022).Nonsense-Mediated Decay Targeted RNA (ntRNA): Proposal of a ntRNA–miRNA–lncRNA Triple Regulatory Network Usable as Biomarker of Prognostic Risk in Patients with Kidney Cancer.Genes,13(9).

Zhou，Zhiyue,et al."Nonsense-Mediated Decay Targeted RNA (ntRNA): Proposal of a ntRNA–miRNA–lncRNA Triple Regulatory Network Usable as Biomarker of Prognostic Risk in Patients with Kidney Cancer".Genes 13.9(2022).